VIVO Cannabis(TM) Completes First Shipment of EU-GMP Medical Grade Cannabis to Beacon Medical Germany GmbH
Toronto, Ontario–(Newsfile Corp. – October 21, 2021) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Company“), a leading medical cannabis company and holder of licenses under the Cannabis Act through its wholly owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc. (“ABcann Medicinals”), today announced that its EU-GMP licensed subsidiary ABcann Medicinals has successfully completed its first shipment of EU-GMP certified Canadian dried flower medical cannabis into Europe.
This follows ABcann Medicinals receiving EU-GMP certification in March 2021, and VIVO’s wholly owned German subsidiary Beacon Medical Germany GmbH receiving an import licence from Germany’s Brandenburg health authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit (“LAVG”), as well as its first import permit from Germany’s BfArM, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) in July 2021.
“This is a monumental milestone for VIVO. We thank our team for their dedication over the last few years to get us to this point,” commented Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer. “We are excited to kick-off VIVO’s commercial business in Germany, as our second international medical cannabis market after Australia. We are confident that our products will be just as successful with patients in Germany as they have proved to be with patients in Australia.”
Beacon Medical Germany GmbH will be responsible for commercialization in Germany. “We look forward to introducing premium quality Beacon Medical™ products to physicians, pharmacists and patients in Europe,” commented Andreas Sander, VIVO’s President of European Operations.
Beacon Medical™ product will undergo full range quality testing for market release in a German GMP-certified specialized lab to ensure the highest product quality and patient safety.
VIVO remains committed to medical cannabis patients in Canada. As demand from international markets grows, consistent supply of Beacon Medical™ product for domestic patients will continue to be a priority. Canadian patients requiring support with registration or placing orders may contact VIVO’s Customer Care Team at 1 (855) 882-0988 or care@vivocannabis.com.
About VIVO Cannabis™
VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 150,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com.
For further information:
VIVO Investor Relations
+1 416-848-9839
ir@vivocannabis.com
Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/
Disclaimer for Forward-Looking Information
Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements. Readers are urged to consider these factors carefully along with the more extensive risk factors included in the Company’s most recent management’s discussion and analysis available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100411
